title: The inhibition of platelet aggregation of metastatic H-ras-transformed 10T1/2 fibroblasts with castanospermine, an N-linked glycoprotein processing inhibitor.
abstract: A series of T24-H-ras-transformed 10T1/2 fibroblasts with varying metastatic potential was tested for the ability to aggregate platelets. Results indicate that although platelet activation was always detected in the highly metastatic cells, some non-metastatic cells also have the ability to cause platelet aggregation, suggesting that this is a necessary but not sufficient characteristic of the metastatic phenotype. Apyrase, an ADP scavenger, effectively inhibited platelet aggregation by metastatic cells, however, there was no significant increase in ADP secretion or relation to the ability of the tumor cells to activate platelets. Hirudin, a thrombin inhibitor, did not affect aggregation, suggesting that the pathway of activation is thrombin-independent. The glycoprotein processing inhibitor, castanospermine, which reduces glycosidase I activity and metastatic capability, inhibited the ability of metastatic cells to cause platelet aggregation. However, another inhibitor of oligosaccharide processing, swainsonine, which inhibits mannosidase II activity and does not reduce metastasis, had no effect on platelet aggregation. These results show that the integrity of N-linked oligosaccharide structure of glycoproteins is an important feature of the ability of ras-transformed fibroblasts to activate platelets.
authors.affiliation: Manitoba Institute of Cell Biology, University of Manitoba, Winnipeg, Canada.
authors.forename: M A
authors.initials: MA
authors.lastname: Spearman
authors.forename: B C
authors.initials: BC
authors.lastname: Ballon
authors.forename: J M
authors.initials: JM
authors.lastname: Gerrard
authors.forename: A H
authors.initials: AH
authors.lastname: Greenberg
authors.forename: J A
authors.initials: JA
authors.lastname: Wright
mesh_terms: D000244:Adenosine Diphosphate / Q000378:metabolism; D000818:Animals; D001081:Apyrase / Q000494:pharmacology; D002460:Cell Line; D002471:Cell Transformation, Neoplastic; D005347:Fibroblasts / Q000502:physiology; D011905:Genes, ras; D005959:Glucosidases / Q000037:antagonists & inhibitors*; D006023:Glycoproteins / Q000096:biosynthesis; D006629:Hirudins / Q000494:pharmacology; D006801:Humans; D066298:In Vitro Techniques; D007212:Indolizines / Q000494:pharmacology*; D007700:Kinetics; D051379:Mice; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D014162:Transfection; D054836:Indolizidines
chemical_list: D000244:Adenosine Diphosphate; D001081:Apyrase; D005959:Glucosidases; D006023:Glycoproteins; D006629:Hirudins; D007212:Indolizines; D010975:Platelet Aggregation Inhibitors; C037806:castanospermine; D054836:Indolizidines